JPWO2007018198A1 - Hla−a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 - Google Patents
Hla−a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 Download PDFInfo
- Publication number
- JPWO2007018198A1 JPWO2007018198A1 JP2007529587A JP2007529587A JPWO2007018198A1 JP WO2007018198 A1 JPWO2007018198 A1 JP WO2007018198A1 JP 2007529587 A JP2007529587 A JP 2007529587A JP 2007529587 A JP2007529587 A JP 2007529587A JP WO2007018198 A1 JPWO2007018198 A1 JP WO2007018198A1
- Authority
- JP
- Japan
- Prior art keywords
- cells
- peptide
- cancer
- killer
- hsp105
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 127
- 206010028980 Neoplasm Diseases 0.000 title claims description 71
- 201000011510 cancer Diseases 0.000 title claims description 48
- 101150051208 HSPH1 gene Proteins 0.000 title abstract description 54
- 102100031624 Heat shock protein 105 kDa Human genes 0.000 title abstract description 54
- 108010074032 HLA-A2 Antigen Proteins 0.000 title abstract description 34
- 102000025850 HLA-A2 Antigen Human genes 0.000 title abstract description 34
- 108091007433 antigens Proteins 0.000 title description 29
- 102000036639 antigens Human genes 0.000 title description 29
- 239000000427 antigen Substances 0.000 title description 28
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 64
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 23
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 13
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000001472 cytotoxic effect Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 6
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 55
- 238000000034 method Methods 0.000 description 30
- 239000002671 adjuvant Substances 0.000 description 16
- 210000004443 dendritic cell Anatomy 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 231100000263 cytotoxicity test Toxicity 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 238000002619 cancer immunotherapy Methods 0.000 description 4
- 229940022399 cancer vaccine Drugs 0.000 description 4
- 238000009566 cancer vaccine Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 238000011398 antitumor immunotherapy Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000028591 pheochromocytoma Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 241000551546 Minerva Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000723554 Pontia occidentalis Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000001400 expression cloning Methods 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 231100000405 induce cancer Toxicity 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100124791 Homo sapiens HSPH1 gene Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011281 bladder sarcoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108700043516 mouse H-2Kb Proteins 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- -1 t-butyloxycarbonyl Chemical group 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
(1) 以下の何れかのペプチド。
(A)配列番号1に示すアミノ酸配列からなるペプチド。
(B)配列番号1に示すアミノ酸配列において1個または2個のアミノ酸が置換又は付加されたアミノ酸配列からなり、キラーT細胞の誘導能を有するペプチド。
(3) (1)に記載のペプチドを少なくとも1種類以上含む、腫瘍の治療及び/または予防のための医薬。
(4) (1)に記載のペプチドを含む、腫瘍反応性T細胞の誘導能の高い抗原提示細胞を誘導するための薬剤。
(A)配列番号1に示すアミノ酸配列からなるペプチド。
(B)配列番号1に示すアミノ酸配列において1個または2個のアミノ酸が置換又は付加されたアミノ酸配列からなり、キラーT細胞の誘導能を有するペプチド。
(7) (1)に記載のペプチドに対する抗体。
(8) (1)に記載のペプチドを用いて誘導される、ヘルパーT細胞、キラーT細胞、又はこれらを含む免疫細胞集団。
(10) (4)または(5)に記載の薬剤によって誘導される、(9)に記載の抗原提示細胞。
(1)本発明のペプチド、及びそれを含む癌に対する免疫誘導剤
本発明のペプチドは以下の何れかのペプチドである。
(A)配列番号1に示すアミノ酸配列からなるペプチド。
(B)配列番号1に示すアミノ酸配列において1個または2個のアミノ酸が置換又は付加されており、キラーT細胞の誘導能を有するペプチド。
本明細書で言うキラーT細胞の誘導能を有するペプチドとは、当該ペプチドを発現する癌を傷害するキラーT細胞を、活性化するペプチドを意味する。
本発明は、上記した本発明のペプチドの一部もしくは全部をエピトープ(抗原)として認識する抗体、並びに該蛋白質又はペプチドを用いてインビトロ刺激により誘導されたキラーT細胞にも関する。一般的には、キラーT細胞のほうが抗体よりも強い抗腫瘍活性を示す。
本発明は、また、本発明のペプチドを用いてインビトロ刺激により誘導されたキラーT細胞にも関する。例えば、末梢血リンパ球や腫瘍浸潤リンパ球を本発明のペプチドでインビトロ刺激すると、腫瘍反応性活性化T細胞が誘導され、この活性化されたT細胞を養子免疫療法に有効に用いることができる。また本発明のペプチドを強力な抗原提示細胞である樹状細胞にインビボあるいはインビトロで発現させて、その抗原発現樹状細胞を投与することにより免疫療法に利用することができる。
本発明のペプチドは、癌細胞特異的キラーT細胞を誘導することができるので、癌の治療、予防剤として期待できる。例えば、本発明のペプチドをコードする遺伝子を適当なベクターに組み込み、この組換えDNAで形質転換されたBCG菌の細菌、または本発明のペプチドをコードするDNAをゲノムに組み込まれたワクシニアウイルス等のウイルスは、ヒト癌の治療・予防用生ワクチンとして有効に利用できる。なお、癌ワクチンの投与量及び投与法は、通常の種痘やBCGワクチンと同様である。
(1)今回検討したHLA-A2に結合することにより、ヒト・キラーT細胞に提示されるHSP105ペプチド
ヒトHSP105のアミノ酸配列についてBIMAS system を用いて検索し、HLA-A2との結合親和性(binding affinity)が比較的に高いと想定されるペプチドを1種類選択した。
HSP105 169-177ペプチドのヒトにおけるキラーT細胞誘導能
(1)採血
熊本大学医学部消化器外科および国立がんセンター東病院にて治療中の、HLA-A2陽性の大腸癌患者からインフォームドコンセントを得た後に、血液サンプル30 mlを得て、先に報告した方法にて( Nakatsura, Tら、Eur.J.Immunol.32,826-836(2002))、Ficoll-Conray密度勾配遠心法により末梢血単核細胞 (PBMC) を単離した。
単離したPBMCから先に報告した方法 (Monji,MらClin Cancer Res10,6047-6057,2004)を用いてキラーT細胞を誘導した。まずMACSを用いてPBMC中のCD8陽性細胞とCD14陽性細胞分画を分離し、CD14陽性細胞分画をGM-CSF (100 ng/ml)とIL-4 (20 ng/ml)と共培養することにより、未成熟樹状細胞を誘導した。さらに培養5日目にTNF-α(20 ng/ml)を添加して樹状細胞を成熟させ、7日目にHSP105 169-177ペプチドを添加(10μM)して、CD8陽性細胞分画と共培養した。この自己CD14陽性細胞分画由来の樹状細胞による抗原刺激を1週毎に3〜4回繰り返し、ペプチド特異的キラーT細胞を誘導した。誘導中メディウムは2日毎に半分交換し、IL-2を10 U/mlの濃度で添加した。
誘導したキラーT細胞の中に、確かにHSP105に特異的に反応してIFN-γを産生するキラーT細胞が存在するかどうかを、ELISPOT法により検討した。標的細胞(ターゲット)に対して、キラーT細胞(エフェクター)が反応してIFN-γを産生すると、赤いスポットとして検出される。IFN-γの検出は、ELISPOT Human IFN-γ ELISPOT set (BD社)を用いて行った。標的細胞として、ペプチドを負荷しないHLA-A2陽性の成熟樹状細胞と、HSP105 A2-7ペプチドを負荷した成熟樹状細胞、HLA-A2陽性でHSP105をあまり発現しないヒト肝癌細胞株HepG2と、HSP105を高発現しHLA-A2陽性のヒト大腸癌細胞株SW620、さらに、HSP105を高発現するが、HLA-A2を発現しないヒトメラノーマ細胞株888melと、HSP105を高発現し、かつHLA-A2を発現するヒトメラノーマ細胞株526mel細胞を用いた。まず、抗ヒト IFN-γ抗体をELISPOTプレート(BD Bioscience社)に18時間コーティングした。その後、10%FCS/RPMIにて2時間ブロッキングを行った。エフェクター細胞(100μL /well)と標的細胞(100μL /well)を混合し、37℃で22時間培養した。エフェクター/ターゲット比(E/T比)は、5:1で実験を行なった。その後、プレートを滅菌水で洗浄し、ビオチン化抗ヒト IFN-γ抗体と2時間、さらにストレプトアビジン-HRPと1時間反応させ、基質溶液にてIFN-γ陽性のスポットを検出した。スポットのカウントは、MINERVA TECH社の自動解析ソフトを用いて行った。この結果、HSP105 169-177ペプチドで誘導したキラーT細胞は、ペプチドを負荷しないHLA-A2陽性の成熟樹状細胞と比べて、HSP105 A2-7ペプチドを負荷した成熟樹状細胞に対して、また、HLA-A2陽性でHSP105をあまり発現しないHepG2 と比べて、HLA-A2陽性でHSP105を高発現するSW620 に対して、さらには、HSP105を高発現するが、HLA-A2を発現しない888mel と比べて、HSP105を高発現し、かつHLA-A2を発現する526mel細胞に対して、より多くのT細胞が強く反応し、スポット数とスポットの面積の総和が有意に増大した(図1)。すなわち、HSP105 169-177ペプチドを用いて、HSP105特異的なキラーT細胞を誘導することができた。
誘導したキラーT細胞の細胞傷害活性は、HLA-A2陽性でHSP105をあまり発現しないヒト肝癌細胞株HepG2と、HLA-A2陽性でHSP105を高発現するヒト大腸癌細胞株SW620を標的として、細胞傷害性試験により検討した。キラーT細胞の細胞傷害活性は、テラスキャンVPによる細胞傷害性試験により評価した。まず、標的細胞を37℃で、30分間カルセインAM染色液にて蛍光標識した。これらの細胞をCoster96穴ハーフ・エリアプレート上でキラーT細胞と共培養し、経時的に蛍光発色細胞を検出することにより細胞傷害の程度を測定した。解析は、MINERVA TECH社の蛍光法による細胞傷害性試験計算処理ソフトCalCt-961にて行った。E/T比は、10:1、20:1、40:1で実験を行なった。この結果、HSP105 169-177ペプチドを用いて誘導したキラーT細胞は、HLA-A2陽性でHSP105をあまり発現しないHepG2 と比べて、HLA-A2陽性でHSP105を高発現するSW620 に対して、明らかに強い細胞傷害活性を示した(図2)。
Claims (10)
- 以下の何れかのペプチド。
(A)配列番号1に示すアミノ酸配列からなるペプチド。
(B)配列番号1に示すアミノ酸配列において1個または2個のアミノ酸が置換又は付加されたアミノ酸配列からなり、細胞傷害性(キラー)T細胞の誘導能を有するペプチド。 - 請求項1に記載のペプチドを少なくとも1種類以上含む、癌に対する免疫誘導剤。
- 請求項1に記載のペプチドを少なくとも1種類以上含む、腫瘍の治療及び/または予防のための医薬。
- 請求項1に記載のペプチドを含む、腫瘍反応性T細胞の誘導能の高い抗原提示細胞を誘導するための薬剤。
- 以下の何れかのペプチドをコードする遺伝子を含む、腫瘍反応性T細胞の誘導能の高い抗原提示細胞を誘導するための薬剤。
(A)配列番号1に示すアミノ酸配列からなるペプチド。
(B)配列番号1に示すアミノ酸配列において1個または2個のアミノ酸が置換又は付加されたアミノ酸配列からなり、キラーT細胞の誘導能を有するペプチド。 - 請求項1に記載のペプチドを含む、腫瘍反応性T細胞を誘導するための薬剤。
- 請求項1に記載のペプチドに対する抗体。
- 請求項1に記載のペプチドを用いて誘導されるキラーT細胞。
- HLA分子と請求項1に記載のペプチドとの複合体を提示する抗原提示細胞。
- 請求項4または5に記載の薬剤によって誘導される、請求項9に記載の抗原提示細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005230671 | 2005-08-09 | ||
JP2005230671 | 2005-08-09 | ||
PCT/JP2006/315630 WO2007018198A1 (ja) | 2005-08-09 | 2006-08-08 | Hla-a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012211774A Division JP2013047230A (ja) | 2005-08-09 | 2012-09-26 | Hla−a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2007018198A1 true JPWO2007018198A1 (ja) | 2009-02-19 |
Family
ID=37727381
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007529587A Pending JPWO2007018198A1 (ja) | 2005-08-09 | 2006-08-08 | Hla−a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 |
JP2012211774A Pending JP2013047230A (ja) | 2005-08-09 | 2012-09-26 | Hla−a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012211774A Pending JP2013047230A (ja) | 2005-08-09 | 2012-09-26 | Hla−a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 |
Country Status (2)
Country | Link |
---|---|
JP (2) | JPWO2007018198A1 (ja) |
WO (1) | WO2007018198A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1536006B1 (en) | 2002-08-30 | 2011-08-24 | Medinet Co., Ltd. | Cancer antigens and utilization thereof |
WO2007018198A1 (ja) * | 2005-08-09 | 2007-02-15 | Kumamoto University | Hla-a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 |
EP3821898A1 (en) * | 2013-03-01 | 2021-05-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
CN105163745B (zh) * | 2013-03-01 | 2020-06-12 | 美国卫生和人力服务部 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
WO2023224096A1 (ja) * | 2022-05-18 | 2023-11-23 | 国立研究開発法人国立がん研究センター | 共通がん抗原カクテルを利用した、がんワクチン、tcr/car-t細胞治療薬、コンパニオン診断方法、および血中循環がん細胞検出によるがんの発症リスク診断方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020624A1 (ja) * | 2002-08-30 | 2004-03-11 | Kumamoto Technology & Industry Foundation | 癌抗原及びその利用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007018198A1 (ja) * | 2005-08-09 | 2007-02-15 | Kumamoto University | Hla-a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 |
-
2006
- 2006-08-08 WO PCT/JP2006/315630 patent/WO2007018198A1/ja active Search and Examination
- 2006-08-08 JP JP2007529587A patent/JPWO2007018198A1/ja active Pending
-
2012
- 2012-09-26 JP JP2012211774A patent/JP2013047230A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020624A1 (ja) * | 2002-08-30 | 2004-03-11 | Kumamoto Technology & Industry Foundation | 癌抗原及びその利用 |
Non-Patent Citations (3)
Title |
---|
JPN6012009362; Proc.Natl.Acad.Sci.USA Vol.89, 1992, p.8918-8922 * |
JPN6012009366; J.Immunol. Vol.160, No.5, 1998, p.2433-2441 * |
JPN6012009370; J.Immunol. Vol.161, No.12, 1998, p.6532-6536 * |
Also Published As
Publication number | Publication date |
---|---|
JP2013047230A (ja) | 2013-03-07 |
WO2007018198A1 (ja) | 2007-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5299942B2 (ja) | HLA−A2陽性者用glypican−3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬 | |
JP5291641B2 (ja) | 癌抗原及びその利用 | |
US9415096B2 (en) | FOXM1 peptide and medicinal agent comprising the same | |
RU2451521C2 (ru) | Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их | |
JP2013047230A (ja) | Hla−a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 | |
JP2004147649A (ja) | 頭頚部癌の抗原 | |
ES2371394T3 (es) | Antígenos de cáncer y su utilización. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090619 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090723 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120228 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120926 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20121004 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20121109 |